Clinical safety and efficacy of first indigenous recombinant hepatitis B vaccine.
Article
in English
| IMSEAR
| ID: sea-95180
ABSTRACT
A pilot study was conducted to assess the clinical safety and immunogenicity of an indigenously developed recombinant hepatitis B vaccine (Shanvac B) in 18 healthy adults. 20 microg of vaccine was administered at 0, 1 and 2 months. Protective anti HBs titres developed in 22%, 77% and 100% one month after 1st, 2nd and 3rd dose of vaccination, respectively. The geometric mean titre after the 3rd dose was 1015.29 mIu/ml. The vaccine was well tolerated with minor local and systemic side effects in 28% and 22%, respectively. The indigenously developed recombinant hepatitis B vaccine is safe, well tolerated and highly immunogenic.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Female
/
Humans
/
Male
/
Vaccines, Synthetic
/
Pilot Projects
/
Adolescent
/
Hepatitis B Vaccines
/
Adult
/
Hepatitis B Antibodies
Language:
English
Year:
1998
Type:
Article
Similar
MEDLINE
...
LILACS
LIS